Seattle Genetics, Inc. (OQ:SGEN)

Business Focus: Biotechnology & Medical Research

Jul 30, 2020 04:02 pm ET
Seattle Genetics Reports Second Quarter 2020 Financial Results
Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2020. The Company also highlighted ADCETRIS (brentuximab vedotin), PADCEV (enfortumab vedotin-ejfv) and TUKYSA (tucatinib) commercial and development accomplishments, as well as progress with its lead pipeline programs to treat cancer.
Jul 09, 2020 08:00 am ET
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2020 financial results on Thursday, July 30, 2020 after the close of financial markets. Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Jun 29, 2020 04:30 pm ET
Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive topline results from the phase 2 single-arm clinical trial known as innovaTV 204 evaluating tisotumab vedotin administered every three weeks for the treatment of patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer.
Jun 18, 2020 08:00 am ET
Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in a phase 1 clinical trial evaluating investigational agent SEA-TGT, also known as SGN-TGT, an anti-TIGIT antibody for patients with solid tumors and lymphomas. TIGIT (T-cell immune receptor with Ig and ITIM domains) is an inhibitory immune receptor that is
Jun 03, 2020 08:00 am ET
Seattle Genetics to Present at Goldman Sachs 41st Annual Global Healthcare Conference
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the virtual Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 11:20 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.s
May 29, 2020 08:00 am ET
Seattle Genetics Announces Positive Results from Exploratory Analyses of HER2CLIMB for TUKYSA™ (tucatinib) in Brain Metastases Patients With HER2-Positive Breast Cancer
Seattle Genetics, Inc. today announced positive results from exploratory analyses of intracranial efficacy, including survival, in patients with HER2-positive metastatic breast cancer (MBC) who had stable or active brain metastases in the HER2CLIMB pivotal trial of TUKYSA™ (tucatinib). HER2CLIMB compared TUKYSA in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with unresectable, locally advanced or metastatic HER2-positive breast cancer with or without brain metastases. Of the patients enrolled in the trial, 48 percent had a presence
May 18, 2020 08:00 am ET
Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Virtual Annual Meeting II on June 22-24, 2020
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced highlights from 12 presentations showcasing its research and development portfolio of novel targeted therapies and antibody-drug conjugate (ADC) technology advances and innovation will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being
May 14, 2020 08:00 am ET
Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the current conditional marketing authorization for ADCETRIS® (brentuximab vedotin) to include treatment of adult patients with previously untreated syste
May 13, 2020 05:12 pm ET
Seattle Genetics Highlights Data from Expanding Oncology Portfolio During Virtual Scientific Program of the 2020 ASCO Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the presentation of new data from its expanding pipeline of marketed and investigational therapies in the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 29-31. Thirteen abstracts — including an oral presentation of new
May 12, 2020 08:00 am ET
Seattle Genetics Announces the Approval of TUKYSA™ (tucatinib) in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA™ (tucatinib) tablets in combination with trastuzumab and capecitabine, for the treatment of patients with metastatic HER2-positive breast cancer, who have previously received two or more anti-HER2 re
May 05, 2020 08:00 am ET
Seattle Genetics to Present at the BofA Securities Virtual Health Care Conference 2020
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the BofA Securities Virtual Health Care Conference 2020 on Tuesday, May 12, 2020 at 11:40 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com
Apr 30, 2020 04:02 pm ET
Seattle Genetics Reports First Quarter 2020 Financial Results
Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the first quarter ended March 31, 2020. The Company also highlighted ADCETRIS (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) commercial and development accomplishments, TUKYSA (tucatinib) U.S. Food and Drug Administration (FDA) approval and launch as well as progress with its lead programs to treat cancer.
Apr 24, 2020 08:00 am ET
Seattle Genetics Announces Change to Virtual Format for 2020 Annual Meeting
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that, due to public health and safety concerns related to the coronavirus (COVID-19) pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its shareholders, employees and others, Seattle Genetics is changing its 2020 Annual Meeting of Shareholders (the “Annual Meeting”) to a virtual-only format.
Apr 17, 2020 02:27 pm ET
Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) granted approval to TUKYSA™ (tucatinib) tablets in combination with trastuzumab and capecitabine for adult patients with advanced unresectable (cannot be surgically removed) or metastatic HER2-positive breast cancer, including patients with brain
Apr 13, 2020 08:00 am ET
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2020 Financial Results on April 30, 2020
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2020 financial results on Thursday, April 30, 2020 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Apr 08, 2020 08:00 am ET
Seattle Genetics to Webcast Virtual Fireside Chat at Needham Healthcare Conference
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat at the Needham Healthcare Conference on Tuesday, April 14, 2020 at 12:00 p.m. Eastern Time. The conference will be held in a virtual meeting format. The presentation will be webcast live and available for replay from Seattle Genetics’ website at
Apr 02, 2020 08:00 am ET
Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advance
Seattle Genetics, Inc. (Nasdaq:SGEN) today provided an update on the phase 1b/2 multicohort EV-103 trial (also known as KEYNOTE-869) of PADCEVTM (enfortumab vedotin-ejfv) in combination with anti-PD-1 therapy pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who a
Mar 10, 2020 08:00 am ET
Seattle Genetics to Webcast Virtual Fireside Chat at Barclays Global Healthcare Conference
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay Siegall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 11, 2020 at 4:20 p.m. Eastern Time. The conference will be held in a virtual meeting format. The presentation will be webcast live and available for replay from Seattle Genetics’ website at
Mar 02, 2020 08:00 am ET
Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the cancellation of the Company’s presentation and webcast at the Cowen 40th Annual Healthcare Conference on Tuesday, previously scheduled to take place on March 3, 2020 at 9:20 a.m. Eastern Time. Management will no longer be attending the conference as a precautionary measure related to travel amidst the evolving coronavirus situation.
Feb 26, 2020 08:00 am ET
Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.
Feb 13, 2020 08:00 am ET
Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Company’s New Drug Application (NDA) for the investigational medicine tucatinib. This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patient
Feb 06, 2020 04:02 pm ET
Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results
Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2019. The Company also highlighted ADCETRIS (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) commercial, regulatory and clinical development accomplishments and progress with its clinical programs for cancer, including tucatinib.
Jan 31, 2020 08:00 am ET
EMA Validates Seattle Genetics’ Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for tucatinib, in combination with trastuzumab and capecitabine, for the treatment of adult patients with locally advanced unresectable or metastatic HER2-positive breast cancer, includin
Jan 21, 2020 08:30 am ET
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2019 financial results on Thursday, February 6, 2020 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Jan 21, 2020 08:00 am ET
Seattle Genetics Achieves Milestone Following European Commission Approval of Roche’s Polivy® (Polatuzumab Vedotin)
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive a milestone payment from Roche triggered by European Commission conditional marketing authorisation for Polivy® (polatuzumab vedotin). Polivy is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ technology. It was developed and is commercialized by Roche/Genentech. Polivy was approved in combination with bendamustine plus MabThera® (rituximab) (BR) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a
Jan 06, 2020 08:00 am ET
Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. Pacific Time. Both the presentation and question and answer session that follows at 3:00 p.m. will be webcast live and available for replay from Seattle Genetics’ website at
Dec 23, 2019 08:00 am ET
Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tucatinib. This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or m
Dec 18, 2019 06:42 pm ET
Seattle Genetics to Host Conference Call and Webcast on December 19, 2019 to Discuss PADCEVTM (enfortumab vedotin-ejfv) Approval
Seattle Genetics, Inc. (Nasdaq: SGEN) will host a conference call and webcast on Thursday, December 19, 2019 to discuss the U.S. Food and Drug Administration approval of PADCEVTM (enfortumab vedotin-ejfv). Access to the event can be obtained as follows:
Dec 18, 2019 08:00 am ET
Seattle Genetics Announces U.S. FDA Grants Breakthrough Therapy Designation for Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tucatinib, in combination with trastuzumab and capecitabine, for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients wit
Dec 11, 2019 09:54 am ET
Seattle Genetics Announces Positive Tucatinib HER2CLIMB Trial Results in Locally Advanced or Metastatic HER2-Positive Breast Cancer Presented at 2019 SABCS and Published in the New England Journal of
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive pivotal data from the HER2CLIMB trial evaluating tucatinib in patients with HER2-positive metastatic breast cancer (MBC) were presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) and simultaneously published in the
Dec 09, 2019 10:00 am ET
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 trials of ADCETRIS® (brentuximab vedotin). These analyses were presented at the 61st Annual Meeting of the American So
Dec 07, 2019 02:00 pm ET
Seattle Genetics Announces Updated Data of ADCETRIS® (Brentuximab Vedotin) in Combination with OPDIVO® (Nivolumab) in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced updated and long-term follow-up analyses from two clinical trials evaluating ADCETRIS (brentuximab vedotin) and OPDIVO® (nivolumab) in frontline Hodgkin lymphoma (HL) patients aged 60 years and older and in relapsed or refractory classical HL. ADCETRIS is an antibody-drug
Nov 25, 2019 08:00 am ET
Seattle Genetics Announces Health Canada Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Health Canada has approved the supplemental New Drug Submission that expands the use of ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) chemotherapy for the treatment of previously untreated adult patients with systemic anaplast
Nov 12, 2019 05:15 pm ET
Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it has submitted an arbitration demand to the American Arbitration Association to resolve its dispute with Daiichi Sankyo Co. Ltd. regarding the ownership of certain technology used by Daiichi Sankyo in its metastatic breast cancer drug candidate (DS-8201, [Fam-] trastuzumab deruxtecan), among
Nov 07, 2019 08:00 am ET
Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from its ADCETRIS® (brentuximab vedotin) clinical development program at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 7-10 in Orlando, Fla. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marke
Nov 05, 2019 08:00 am ET
Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate
Seattle Genetics, Inc. (Nasdaq: SGEN) and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160) today announced that the companies have entered into a license agreement for an advanced preclinical product candidate for treating cancer. The agent utilizes a proprietary Seattle Genetics antibody-based technology and is expected to advance into clinical trials in t
Nov 04, 2019 11:51 pm ET
Seattle Genetics Responds to Daiichi Sankyo’s Complaint for Declaratory Judgment
Seattle Genetics, Inc. (Nasdaq:SGEN) today released the following statement in response to Daiichi Sankyo’s filing of a Declaratory Judgment action alleging Seattle Genetics is not entitled to intellectual property rights under a collaboration between the two companies for the development of antibody-drug conjugates (ADCs):
Nov 04, 2019 08:00 am ET
Seattle Genetics to Present at Credit Suisse 28th Annual Healthcare Conference
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 10:20 a.m. Mountain Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.
Oct 29, 2019 04:02 pm ET
Seattle Genetics Reports Third Quarter 2019 Financial Results
Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2019. The Company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development activities and progress with its late-stage oncology portfolio.
Oct 21, 2019 06:45 am ET
Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive topline results from the HER2CLIMB trial, a randomized, double-blind, placebo-controlled, active comparator pivotal trial evaluating tucatinib. The trial compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with locally advan
Oct 10, 2019 08:00 am ET
Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Brea
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in HER2CLIMB-02, a randomized phase 3 clinical trial evaluating investigational agent tucatinib versus placebo, in combination with standard-of-care ado-trastuzumab emtansine (T-DM1, Kadcyla®), for patients with locally advanced or metastatic HER2-positive (HE
Oct 08, 2019 08:00 am ET
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2019 Financial Results on October 29, 2019
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2019 financial results on Tuesday, October 29, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Sep 29, 2019 09:00 am ET
Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that initial data were presented from the single arm phase 2 clinical trial known as MOUNTAINEER. The trial is evaluating the investigational agent tucatinib in combination with trastuzumab (Herceptin®) in patients with HER2-positive (HER2+), RAS wild-type metastatic colorectal cancer (m
Sep 28, 2019 02:30 am ET
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Blad
BOTHELL, Wash. and TOKYO, Sept. 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced initial results from the phase 1 clinical trial EV-103. Forty-five patients were evaluated for safety with the combination of the investigational agent enfortumab vedotin and the immune therapy pembrolizumab in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for treatment with cisplatin-based chemotherapy. The study met outcome measures f...
Sep 28, 2019 02:30 am ET
Sep 17, 2019 08:00 am ET
Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the European Society for Medical Oncology (ESMO) 2019 Congress
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that new data from four of its investigational programs will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, from September 27 - October 1, 2019.
Sep 16, 2019 08:00 am ET
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
BOTHELL, Wash. and TOKYO, Sept. 16, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin and granted Priority Review for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally ad...
Jul 26, 2019 11:49 am ET
Seattle Genetics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the completion of its previously announced underwritten public offering of 8,214,286 shares of its common stock at a price to the public of $70.00 per share, including 1,071,428 shares sold pursuant to the exercise in full of the underwriters' overallotment option to purchase additional shares. All of the shares were sold by Seattle Genetics. Including the option exercise, the aggregate gross proceeds to Seattle Genetics from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately
Jul 23, 2019 10:26 pm ET
Seattle Genetics Announces Pricing of Public Offering of Common Stock
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 7,142,858 shares of its common stock at a price to the public of $70.00 per share. All of the shares are being sold by Seattle Genetics. The gross proceeds to Seattle Genetics from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $500 million. The offering is expected to close on or about July 26, 2019, subject to customary closing conditions. In addition, Seattle Genetics has granted the underwriters of the off
Jul 23, 2019 04:09 pm ET
Seattle Genetics Announces Proposed Public Offering of Common Stock
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares are being offered by Seattle Genetics. In addition, Seattle Genetics expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 900,000 shares of its common stock solely to cover overallotments at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering
Jul 16, 2019 04:02 pm ET
Seattle Genetics Reports Second Quarter 2019 Financial Results
Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2019. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development accomplishments and progress with its late-stage clinical programs for cancer.
Jul 16, 2019 02:30 pm ET
Seattle Genetics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 16, 2019 / Seattle Genetics, Inc. (NASDAQ: SGEN) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 16, 2019 at 4:30 PM Eastern Time.
Jul 16, 2019 08:00 am ET
Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
TOKYO and BOTHELL, Wash., July 16, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced submission of a Biologics License Application for accelerated approval to the U.S. Food and Drug Administration for the investigational agent enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastati...
Jul 16, 2019 08:00 am ET
Jul 02, 2019 08:00 am ET
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2019 Financial Results on July 16, 2019
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2019 financial results on Tuesday, July 16, 2019 after the close of financial markets. Following the announcement, management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Jun 12, 2019 08:00 am ET
Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (I
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from its ADCETRIS® (brentuximab vedotin) clinical development program at the 24th Annual Congress of the European Hematology Association (EHA) taking place June 13-16 in Amsterdam; and the International Conference on Malignant Lymphoma
Jun 10, 2019 12:51 pm ET
Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of Polivy™ (polatuzumab vedotin-piiq), which is an antibody-drug conjugate (ADC) targeting CD79b that utilizes Seattle Genetics’ technology. Polivy was developed and will be commercialized by Genentech, a member of the Roche Group. It was approved in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at leas
Jun 03, 2019 08:00 am ET
Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS® (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced additional analyses of results from ECHELON-1 and ECHELON-2, the frontline phase 3 trials of ADCETRIS® (brentuximab vedotin), at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2019 in Chicago. The E
May 21, 2019 08:00 am ET
Seattle Genetics Appoints Robin Taylor, Ph.D., Chief Commercial Officer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Robin G. Taylor, M.B.A., Ph.D., as Chief Commercial Officer. Dr. Taylor brings 18 years of biotechnology and pharmaceutical company experience in the commercialization of oncology drugs, including significant marketing, launch and global product strategy roles at both Genentech/Roche and AstraZeneca. He contributed to several leading global brands, including TECENTRIQ® (atezolizumab), ALECENSA® (alectinib), AVASTIN® (bevacizumab) and HERCEPTI
May 15, 2019 05:10 pm ET
Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology (ASCO) Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from six of its proprietary programs will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting taking place May 31 to June 4, 2019 in Chicago. More than 10 sessions at the meeting will feature Seattle Genetics’ appro
May 15, 2019 08:00 am ET
Seattle Genetics to Present at RBC Capital Markets 2019 Global Healthcare Conference
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the RBC Capital Markets 2019 Global Healthcare Conference on Wednesday, May 22, 2019 at 8:30 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com i
May 03, 2019 12:09 pm ET
Seattle Genetics Announces Progress in Expanding ADCETRIS® (Brentuximab Vedotin) Indications in Canada
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Health Canada has approved the supplemental New Drug Submission that expands the use of ADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin, vinblastine and dacarbazine) chemotherapy in patients with previously untreated Stage IV Hodgkin lymp
Apr 25, 2019 04:02 pm ET
Seattle Genetics Reports First Quarter 2019 Financial Results
Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the first quarter ended March 31, 2019. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development accomplishments and progress with its late-stage clinical programs for cancer.
Apr 10, 2019 07:25 am ET
Analysis: Positioning to Benefit within The Allstate, Seattle Genetics, Intra-Cellular Therapies, AMN Healthcare Services, AVX, and DURECT — Research Highlights Growth, Revenue, and Consolidated Resul
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Allstate Corporation (NYSE:ALL), Seattle Genetics, Inc. (NASDAQ:SGEN),...
Apr 04, 2019 08:00 am ET
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Mar 29, 2019 08:00 am ET
Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced completion of enrollment in the potentially pivotal innovaTV 204 phase 2 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer who have relapsed or progre
Mar 28, 2019 07:00 am ET
Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin
Seattle Genetics, Inc. (Nasdaq:SGEN) will host a conference call and webcast discussion regarding the positive topline results from its pivotal clinical trial of enfortumab vedotin in locally advanced or metastatic urothelial cancer, which were announced in a press release earlier today. Access to the event can b
Mar 28, 2019 03:01 am ET
Mar 28, 2019 03:01 am ET
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
BOTHELL, Wash. and TOKYO, March 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the first cohort of patients in a pivotal phase 2 single-arm clinical trial known as EV-201. The cohort is evaluating enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received previous treatment with both platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor. Results showed a 44 percent object...
Mar 27, 2019 08:00 am ET
Seattle Genetics Highlights Antibody-Drug Conjugate Innovation and Immuno-Oncology Program at the American Association for Cancer Research (AACR) Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data highlights from six presentations showcasing technology advances in the company’s antibody-drug conjugate (ADC) platform and an immuno-oncology program at the American Association for Cancer Research (AACR) Annual Meeting 2019 being held March 29-April 3, 2
Mar 05, 2019 08:00 am ET
Seattle Genetics to Present at Cowen and Company 39th Annual Health Care Conference
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 10:40 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com
Feb 13, 2019 07:35 am ET
New Research: Key Drivers of Growth for Phillips 66, Seattle Genetics, Green Plains, C&J Energy Services, FRP, and Medical Transcription Billing — Factors of Influence, Major Initiatives and Sustained
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Phillips 66 (NYSE:PSX), Seattle Genetics, Inc. (NASDAQ:SGEN), Green...
Feb 11, 2019 08:00 am ET
Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS® (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing authorization for ADCETRIS (brentuximab vedotin) to include ADCETRIS in combination with AVD (Adriamycin®, vinblastine
Feb 07, 2019 04:02 pm ET
Seattle Genetics Reports Fourth Quarter and Full Year 2018 Financial Results
Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2018. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development accomplishments and progress with its late-stage clinical programs for cancer.
Feb 06, 2019 08:00 am ET
Seattle Genetics to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 2:00 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com
Jan 22, 2019 08:00 am ET
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Jan 09, 2019 08:00 am ET
Dec 19, 2018 08:00 am ET
Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:30 p.m. Pacific Time. Both the presentation and question and answer session that follows at 3:00 p.m. will be webcast live and available for replay from Seattle Genetics’ website at
Dec 10, 2018 07:45 am ET
Report: Developing Opportunities within Covanta Holding, Zscaler, Avaya, Seattle Genetics, Viad, and Canada Goose — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Covanta Holding Corporation (NYSE:CVA), Zscaler, Inc. (NASDAQ:ZS), Avaya...
Dec 02, 2018 12:00 pm ET
Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from the ECHELON-1 phase 3 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin®, vinblastine and dacarbazine) in newly diagnosed stage III or IV classical Hodgkin lymphoma (HL) at the 60th Ame
Dec 01, 2018 12:00 pm ET
Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from three ongoing clinical trials evaluating the combination of ADCETRIS (brentuximab vedotin) and Opdivo (nivolumab) at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, Calif., Dece
Nov 26, 2018 08:00 am ET
Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 3, 2018 during the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, Calif. The program will feature the phase 3 ECHELON-2 trial as well as other key data from the meeting.
Nov 16, 2018 10:52 am ET
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-E
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for ADCETRIS® (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.S. Food and Drug Administration (FDA) for adults with previously untreated systemic anaplastic large cell lym
Nov 15, 2018 08:00 am ET
FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ADCETRIS (brentuximab vedotin) for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including
Nov 14, 2018 08:00 am ET
Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SEA-BCMA for patients with relapsed or refractory multiple myeloma (MM). SEA-BCMA is an investigational antibody empowered using Seattle Genetics’ proprietary Sugar
Nov 06, 2018 08:00 am ET
Seattle Genetics to Present at the Credit Suisse 27th Annual Healthcare Conference
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13, 2018 at 2:15 p.m. Mountain Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com
Nov 05, 2018 08:00 am ET
Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 ECHELON-2 trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline tre
Nov 01, 2018 04:05 pm ET
Seattle Genetics Announces More Than 30 Presentations at ASH 2018 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Program
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that 31 abstracts featuring data from the broad ADCETRIS (brentuximab vedotin) development program have been accepted for presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition taking place from December 1-4, 2018 i
Oct 31, 2018 07:50 am ET
New Research: Key Drivers of Growth for Covanta Holding, Seattle Genetics, DSW, Canada Goose, Oaktree Capital Group, and Arthur J. Gallagher — Factors of Influence, Major Initiatives and Sustained Pro
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Covanta Holding Corporation (NYSE:CVA), Seattle Genetics, Inc....
Oct 26, 2018 08:00 am ET
Seattle Genetics Announces Multiple Data Presentations Evaluating ADCETRIS® (Brentuximab Vedotin) in Patients with Hodgkin Lymphoma at ISHL 2018
Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted multiple presentations evaluating ADCETRIS (brentuximab vedotin) across a broad range of Hodgkin lymphoma (HL) settings at the 11th International Symposium on Hodgkin Lymphoma (ISHL) taking place in Cologne, Germany, October 27-29, 2018. Data include
Oct 25, 2018 04:02 pm ET
Seattle Genetics Reports Third Quarter 2018 Financial Results
Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2018. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development accomplishments and progress with its late-stage clinical programs for cancer.
Oct 08, 2018 06:50 pm ET
Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress
Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that updated clinical data from the innovaTV 201 Phase II study evaluating tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer will be presented as a poster at the European Society for Medical Oncology (ESMO) 2018 Congress taking place in Munich, Germany from October 19 to 23, 2018. Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) designed to target the Tissue Factor antigen, which is expressed on a broad
Oct 03, 2018 08:00 am ET
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 25, 2018
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter financial results on Thursday, October 25, 2018 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Oct 03, 2018 07:50 am ET
Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding, Summit Midstream Partners, LP, and Seattle Genetics with Renewed Outlook — Fundamental Analy
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Helmerich Payne, Inc....
Oct 01, 2018 06:45 am ET
Sep 21, 2018 10:48 am ET
Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) as a front
Sep 04, 2018 08:00 am ET
Seattle Genetics to Present at the Morgan Stanley Global Healthcare Conference
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 2:05 p.m. EDT. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors sectio
Jul 26, 2018 04:02 pm ET
Seattle Genetics Reports Second Quarter 2018 Financial Results
Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2018. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development accomplishments and progress with its late-stage clinical programs for cancer.
Jul 12, 2018 08:00 am ET
Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2
Jul 11, 2018 10:41 am ET
CORRECTING and REPLACING Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer
The second bullet point above the "About Tucatinib" boilerplate, should read: "ORR was 47 percent (n=16/34)" (instead of "ORR was 47 percent (n=34/50)").
Jul 09, 2018 08:00 am ET
Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenj
Jul 09, 2018 08:00 am ET
Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
BOTHELL, Wash., and TOKYO, July 9, 2018 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced completion of enrollment for the enfortumab vedotin EV-201 pivotal phase 2 clinical trial cohort of patients with locally advanced or metastatic urothelial cancer who have been previously treated with both platinum chemotherapy and a checkpoint inhibitor (PD-L1 or PD-1). Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) that targets Nectin-4. ...
Jun 28, 2018 08:00 am ET
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 26, 2018
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter financial results on Thursday, July 26, 2018 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Jun 26, 2018 07:45 am ET
Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics — Research Highlights Growth, Revenue, and Consolidated Resu
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Manitowoc Company, Inc. (NYSE:MTW), Omeros Corporation (NASDAQ:OMER),...
Jun 13, 2018 08:00 am ET
Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standar
Jun 06, 2018 08:00 am ET
Seattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 1:20 p.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com
Jun 04, 2018 09:00 am ET
Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from the phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy in newly diagnosed stage III or IV classical Hodgkin lymphoma (HL) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 03, 2018 09:00 am ET
Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
TOKYO and BOTHELL, Wash., June 3, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the presentation of updated phase 1 data of enfortumab vedotin, an investigational antibody-drug conjugate (ADC), at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago. In this phase 1 study (EV-101), enfortumab vedotin was evaluated as monotherapy for patients with metastatic urothelial cancer including patients who previously received a checkpoint inhibitor.i This ...
May 17, 2018 09:00 am ET
Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Roger D. Dansey, M.D., as Chief Medical Officer. Dr. Dansey brings extensive experience in cancer drug development, most recently from Merck Inc. where he was Therapeutic Area Head for Late Stage Oncology, responsible for the ongoing registration efforts for KEYTRUDA® (pembrolizumab) across multiple tumor types.
May 17, 2018 08:00 am ET
Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts from its robust clinical development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, from June 1-5, 2018.
May 09, 2018 07:45 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Patterson Companies, Zayo Group, Six Flags Entertainment Corporation New, Leucadia National, Seattle Genetics, and RPC — New Researc
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Patterson Companies, Inc. (NASDAQ:PDCO), Zayo Group Holdings, Inc....
May 02, 2018 08:00 am ET
Seattle Genetics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018 at 5:00 p.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com
Apr 26, 2018 04:02 pm ET
Seattle Genetics Reports First Quarter 2018 Financial Results
Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the first quarter ended March 31, 2018. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development accomplishments, and progress with its late-stage clinical programs and pipeline of targeted therapie
Apr 12, 2018 08:00 am ET
Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data highlights from nine presentations showcasing the company’s innovative, proprietary antibody-drug conjugate (ADC) platform technologies as well as its emerging immuno-oncology pipeline. Data include preclinical and clinical advances with ADCETRIS®
Apr 05, 2018 08:00 am ET
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter financial results on Thursday, April 26, 2018 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Mar 26, 2018 08:00 am ET
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
TOKYO and BOTHELL, Wash., March 26, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors (CPI). ...
Mar 26, 2018 08:00 am ET
Mar 20, 2018 12:48 pm ET
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) in combination with chemotherapy in adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma. The approval is based on the successful outcome
Mar 15, 2018 08:00 am ET
Seattle Genetics Appoints Dr. Alpna Seth to Board of Directors
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Alpna Seth, Ph.D. has been appointed to the company’s Board of Directors. Dr. Seth has more than 20 years of global experience in the healthcare and biotechnology/pharmaceutical industry, including senior leadership positions at Biogen. She currently serves as Chief Operating Officer of Vir Biotechnology, a San Francisco-based biotechnology company focused on transforming the care of people with serious infectious diseases.
Mar 13, 2018 08:00 am ET
Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, 2018 at 10:45 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Inv
Mar 09, 2018 09:26 am ET
Seattle Genetics Completes Acquisition of Cascadian Therapeutics
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced it has completed its previously announced acquisition of Cascadian Therapeutics, Inc. The most advanced program in Cascadian Therapeutics’ pipeline is tucatinib, an investigational oral tyrosine kinase inhibitor (TKI) that is highly selective for HER2, a growth factor receptor that is overexpressed in multiple cancers, including breast, colorectal, ovarian and gastric. Tucatinib is currently being evaluated in a randomized global pivotal trial called HER2CLIMB for patients with HER2-positive (
Mar 09, 2018 06:00 am ET
Seattle Genetics Completes Tender Offer for All Shares of Cascadian Therapeutics
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the expiration of the tender offer (the “Offer”) by a wholly owned subsidiary, “Merger Sub”, for all of the shares of common stock of Cascadian Therapeutics, Inc. (Nasdaq:CASC), for a price of $10.00 per share in cash, without interest, less any applicable withholding taxes. The Offer expired at 12:00 midnight, New York City time, on March 9, 2018. Seattle Genetics expects to complete today the acquisition of Cascadian Therapeutics through a merger without a vote of Cascadian Therapeutics stoc
Mar 07, 2018 08:00 am ET
Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma
Seattle Genetics, Inc. (NASDAQ: SGEN) today announced dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SGN-CD48A for patients with relapsed or refractory multiple myeloma (MM). SGN-CD48A is an investigational ADC targeted to the protein CD48, which is highly expresse
Mar 07, 2018 07:45 am ET
Report: Developing Opportunities within Seattle Genetics, PBF Energy, Chipotle Mexican Grill, CIT Group Inc (DEL), PDL BioPharma, and Dollar General — Future Expectations, Projections Moving into 2018
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Seattle Genetics, Inc. (NASDAQ:SGEN), PBF Energy...
Feb 27, 2018 08:00 am ET
Seattle Genetics to Present at Cowen and Company 38th Annual Health Care Conference
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 9:20 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in
Feb 16, 2018 08:00 am ET
Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period
Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) with respect to Seattle Genetics’ proposed acquisition of Cascadian Therapeutics, Inc. (NASDAQ:CASC) expired at 11:59 p.m. on February 15, 2018. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the tender offer and the acquisition. Other offer conditions remain to be satisfied, including among others, a minimum tender of at least a majority o
Feb 09, 2018 06:45 am ET
Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, and Seattle Genetics, Inc....
Feb 09, 2018 06:45 am ET
Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, and Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company developing innovative, targeted therapies for cancer, today announced they have entered into a collaboration and license agreement with the goal of developing multiple targeted bispecific immuno-oncology treatments for solid tumors and blood ca
Feb 08, 2018 05:39 pm ET
Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc.
Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc., has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc. (NASDAQ:CASC) at a price of $10.00 per share net to the seller in cash, without interest, less any applicable withholding taxes (the “Offer”). The Offer is being made in connection with the Agreement and Plan of Merger, dated as of January 30, 2018, among Seattle Genetics, Valley Acquisition Sub, and Casca
Feb 06, 2018 04:02 pm ET
Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results
Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2017. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development accomplishments, enfortumab vedotin (ASG-22ME) and tisotumab vedotin clinical activities,
Feb 06, 2018 12:30 pm ET
Seattle Genetics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 6, 2018 / Seattle Genetics, Inc. (NASDAQ: SGEN) will be discussing their earnings results in their Q4 Earnings Call to be held on February 6, 2018 at 4:30 PM Eastern Time.
Feb 02, 2018 08:30 am ET
Seattle Genetics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,730,769 shares of Seattle Genetics’ common stock. Including this option exercise, total gross proceeds to Seattle Genetics from the offering of an aggregate of 13,269,230 shares at a price to the public of $52.00 per share will be approximately $690.0 million, before deducting the underwriting discounts and commissions and offering expenses. All of the
Feb 01, 2018 06:30 am ET
Seattle Genetics Announces Pricing of Public Offering of Common Stock
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 11,538,461 shares of its common stock at a price to the public of $52.00 per share. All of the shares are being sold by Seattle Genetics. The gross proceeds to Seattle Genetics from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $600.0 million. The offering is expected to close on or about February 5, 2018, subject to customary closing conditions. In addition, S
Jan 31, 2018 06:40 am ET
Seattle Genetics Announces Proposed Public Offering of Common Stock
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has commenced an underwritten public offering of $550.0 million of shares of its common stock. All of the shares are being offered by Seattle Genetics. In addition, Seattle Genetics expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $82.5 million of shares of its common stock solely to cover over-allotments at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other con
Jan 31, 2018 06:30 am ET
Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline
Seattle Genetics, Inc. (Nasdaq:SGEN) and Cascadian Therapeutics, Inc. (Nasdaq:CASC) today announced the signing of a definitive merger agreement under which Seattle Genetics has agreed to acquire Cascadian Therapeutics. Under the terms of the agreement, Seattle Genetics will pay $10.00 per share in cash, or approximat
Jan 22, 2018 08:00 am ET
Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy
Seattle Genetics, Inc. (Nasdaq: SGEN) reported today that its collaborator, Takeda Pharmaceutical Company Limited, announced that the European Commission has extended the current conditional marketing authorization for ADCETRIS (brentuximab vedotin) to include the treatment of adult patients with CD30-positive cuta
Jan 18, 2018 08:00 am ET
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2017 financial results on Tuesday, February 6, 2018 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Jan 08, 2018 08:00 am ET
Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference
Seattle Genetics, Inc. (NASDAQ: SGEN) highlighted today the progress of its pipeline of antibody-drug conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference. Through both internal efforts and that of its collaborators, the company’s ADC technology is being employed in more than 20 program
Jan 02, 2018 08:00 am ET
FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) for ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin
Dec 19, 2017 08:00 am ET
Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 10:30 a.m. Pacific Time. Both the presentation and question and answer session that follows at 11:00 a.m. will be webcast live and available for replay from Seattle Genetics’ website at
Dec 10, 2017 09:00 am ET
Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted final five-year survival results from a phase 1 clinical trial evaluating ADCETRIS (brentuximab vedotin) in mature T-cell lymphoma (MTCL) at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Atlanta, Georgia
Dec 09, 2017 09:00 am ET
Seattle Genetics Highlights Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma at ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted updated results from the phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in CD30-expressing cutaneous T-cell lymphoma (CTCL) at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Atla
Dec 07, 2017 08:00 am ET
Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium
Seattle Genetics, Inc. (NASDAQ: SGEN) today announced updated data from an ongoing phase 1 clinical trial evaluating ladiratuzumab vedotin in patients with metastatic triple negative breast cancer (TNBC) at the 2017 San Antonio Breast Cancer Symposium (SABCS), taking place December 5-9, 2017. Ladiratuzumab vedotin
Dec 04, 2017 08:00 am ET
Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 11, 2017 during the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, GA. Industry experts will discuss the ADCETRIS® (brentuximab vedotin) phase 3 ECHELON-1 data, and members of the Seattle Genetics management team will discuss other program highlights.
Nov 10, 2017 08:30 am ET
Report: Exploring Fundamental Drivers Behind Tronox, Ameren, GrubHub, Patterson Companies, AVEO Pharmaceuticals, and Seattle Genetics – New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 10, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tronox Limited (NYSE:TROX), Ameren Corporation (NYSE:AEE),...
Nov 09, 2017 12:40 pm ET
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior sys
Nov 08, 2017 08:00 am ET
Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
TOKYO and BOTHELL, Wash., Nov. 8, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas"), and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced dosing of the first patient in EV-103, a phase 1b clinical trial evaluating the safety and tolerability of enfortumab vedotin in combination with pembrolizumab or atezolizumab, two types of immune checkpoint inhibitor (CPI) therapies, for first- or second-line treatment of patients with locally advanced or metastatic urothelial cancer. Enfortumab vedotin is an investigational antibody-drug conjuga...
Nov 08, 2017 08:00 am ET
Nov 02, 2017 08:00 am ET
Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 ECHELON-1 trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline tre
Nov 01, 2017 09:00 am ET
Seattle Genetics to Present Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program at ASH 2017
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that 18 abstracts featuring data from the broad ADCETRIS (brentuximab vedotin) development program have been accepted for presentation, including a plenary presentation, at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition ta
Oct 26, 2017 04:02 pm ET
Seattle Genetics Reports Third Quarter 2017 Financial Results
Seattle Genetics, Inc. (NASDAQ: SGEN) today reported financial results for the third quarter and nine months ended September 30, 2017. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development accomplishments, enfortumab vedotin (ASG-22ME) and tisotumab vedotin clinical act
Oct 11, 2017 08:00 am ET
Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer
Seattle Genetics, Inc. (NASDAQ: SGEN) today announced two clinical collaboration agreements for the evaluation of SGN-LIV1A in patients with triple negative breast cancer (TNBC). SGN-LIV1A is an investigational antibody-drug conjugate (ADC) that targets the cell surface protein LIV-1, which is expressed on multiple
Oct 10, 2017 09:00 am ET
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
TOKYO and BOTHELL, Wash., Oct. 10, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics Inc., (NASDAQ: SGEN) today announced dosing of the first patient in EV-201, a registrational phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with checkpoint inhibitor (CPI) therapy. The EV-201 study will assess the antitumor activity and safety of enfortumab vedotin to support potential registration under the U.S. Food and Drug Administra...
Oct 10, 2017 08:00 am ET
Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yos
Oct 10, 2017 06:44 am ET
Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer
Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (NASDAQ: SGEN) announced today a decision to start a Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer. The study could provide the basis for a regulatory application for approval. Tisotumab vedotin consists of a tissue factor (TF)-targeted antibody linked to the cell-killing agent monomethyl auristatin E (MMAE). TF is a protein expressed on a broad range of solid tumors. The Phase II trial is single arm and includes about 100 pat
Oct 05, 2017 08:00 am ET
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 26, 2017
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter financial results on Thursday, October 26, 2017 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Jun 05, 2017 11:45 am ET
Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer at 2017 ASCO Annual Meeting
CHICAGO, June 5, 2017 /PRNewswire/ -- Astellas and Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted updated phase 1 data for enfortumab vedotin (ASG-22ME) studied as monotherapy treatment for metastatic urothelial cancer (mUC) in an oral presentation at the American Society of Clinical Oncology (ASCO) 52nd Annual Meeting in Chicago. Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) that targets Nectin-4, a cell surface protein expressed in multiple solid tumors including mUC, ovarian cancer, and non-small cell lung cancer (NSCLC). Based on the data from the ongoin...
Mar 10, 2017 09:00 am ET
DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 - SGEN
NEW YORK, March 10, 2017 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:...
Mar 05, 2017 09:00 am ET
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Seattle Genetics Inc
STEVENSON, Md., March 05, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of purchasers of Seattle Genetics Inc. (Nasdaq:SGEN) (“Seattle Genetics” or the “Company”) securities during the period between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until March 13, 2017 to seek appointment as lead pla...
Mar 03, 2017 10:19 am ET
Immunomedics Board Institutes Measures As Stockholder Fiduciaries To Preserve Their Best Business Judgment To Protect The Rights Of All Stockholders
MORRIS PLAINS, N.J., March 3, 2017 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) ("Immunomedics" or "the Company") today announced that on behalf of all stockholders, it will continue to pursue legally justified relief against venBio Select Advisor LLC ("venBio") and venBio's four director candidates in the United States District Court for the District of Delaware (the "Federal Action") for their unlawful proxy fight that continues to violate a myriad of federal securities laws. As a result of these violations, venBio has interfered with the voting franchise of Immunomedics' stockholders...
Mar 02, 2017 06:34 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Seattle Genetics Inc. -- SGEN
NEW YORK, March 2, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Seattle Genetics Inc. securities (NASDAQ: SGEN) from October 27, 2016 through December 23, 2016, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Seattle Genetics investors under the federal securities laws....
Feb 28, 2017 06:00 pm ET
IMPORTANT SEATTLE GENETICS INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the Western District of Washingt
NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. (“Seattle Genetics” or the “Company”) (NASDAQ:SGEN) and certain of its officers.  The class action, filed in United States District Court for the Western District of Washington is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Seattle Genetics securities between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”)....
Feb 27, 2017 08:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle Genetics Inc. of Class Action Lawsuit and Upcoming Deadline – SGEN
NEW YORK, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. (“Seattle Genetics” or the “Company”) (NASDAQ:SGEN) and certain of its officers.   The class action, filed in United States District Court, Western District of Washington, and docketed under 17-cv-00041, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Seattle Genetics securities between October 27, 2016 and December 23, 2016, both dates inclusive (the “Class Period”), seeking to recover compensable dam...
Feb 27, 2017 08:00 am ET
Immunomedics Issues Open Letter Highlighting the Clear Decision to Vote for Immunomedics to Ensure Continued Value Creation
Immunomedics Intends to Implement a Non-Dilutive, Lower Risk and Potentially Higher Reward Strategy that Considers the Interests of ALL Stockholders...
Feb 22, 2017 11:40 am ET
SGEN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017
NEW YORK, Feb. 22, 2017 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased Seattle Genetics Inc. (NASDAQ: SGEN) securities between October 27, 2016 and December 23, 2016....
Feb 17, 2017 12:00 pm ET
Feb 15, 2017 02:39 pm ET
SGEN NOTICE: Rosen Law Firm Reminds Seattle Genetics Inc. Investors of Important Deadline in Class Action – SGEN
NEW YORK, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Seattle Genetics Inc. securities (NASDAQ:SGEN) from October 27, 2016 through December 23, 2016, inclusive (the “Class Period”) of the important March 13, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Seattle Genetics investors under the federal securities laws....
Feb 10, 2017 07:26 am ET
Immunomedics Announces Postponement of 2016 Annual Meeting
MORRIS PLAINS, N.J., Feb. 10, 2017 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) ("Immunomedics" or "the Company") today announced it has postponed the Company's 2016 Annual Meeting of Stockholders previously scheduled for February 16, 2017. The Annual Meeting has been postponed to March 3, 2017 at 10:00 a.m. Eastern Time and will be held at the Executive Offices of Immunomedics, Inc., located at 300 The American Road, Morris Plains, New Jersey 07950. The record date of January 24, 2017 has not changed....
Feb 10, 2017 06:50 am ET
Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties
MORRIS PLAINS, N.J., Feb. 10, 2017 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) ("Immunomedics") today announced that it has entered into an exclusive global licensing agreement with Seattle Genetics, Inc. (NASDAQ: SGEN), an innovative global biotechnology company that develops and commercializes novel antibody-drug conjugates (ADCs) for the treatment of cancer. Under the agreement, Seattle Genetics will develop, fund, manufacture and commercialize IMMU-132, Immunomedics' proprietary solid tumor therapy candidate. ...
Feb 09, 2017 03:23 pm ET
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Seattle Genetics, Inc. To Contact The Firm Before Lead Plaintiff Deadline
NEW YORK, Feb. 9, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Seattle Genetics, Inc. ("Seattle Genetics" or the "Company") (NASDAQ: SGEN) of the March 13, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. ...
Feb 03, 2017 01:03 pm ET
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. (SGEN) To Contact Brower Piven Before The Lead Plaintiff Deadline In
STEVENSON, Md., Feb. 03, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of purchasers of Seattle Genetics Inc. (Nasdaq:SGEN) (“Seattle Genetics” or the “Company”) securities during the period between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until March 13, 2017 to seek appointment as lead p...
Jan 31, 2017 02:18 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Seattle Genetics Inc. – SGEN
NEW YORK, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Seattle Genetics Inc. securities (NASDAQ:SGEN) from October 27, 2016 through December 23, 2016, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Seattle Genetics investors under the federal securities laws....
Jan 27, 2017 08:15 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle Genetics Inc. of Class Action Lawsuit and Upcoming Deadline – SGEN
NEW YORK, Jan. 27, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. (“Seattle Genetics” or the “Company”) (NASDAQ:SGEN) and certain of its officers.   The class action, filed in United States District Court, Western District of Washington, and docketed under 17-cv-00041, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Seattle Genetics securities between October 27, 2016 and December 23, 2016, both dates inclusive (the “Class Period”), seeking to recover compensable d...
Jan 21, 2017 01:01 pm ET
SEATTLE GENETICS (SGEN) ALERT: Johnson & Weaver, LLP Announces Filing of Class Action Complaint Against Seattle Genetics, Inc.; Encourages all Investors to Contact the Firm for Information
SAN DIEGO, Jan. 21, 2017 /PRNewswire/ -- Johnson & Weaver, LLP announces that a class action complaint was filed on behalf of purchasers of Seattle Genetics, Inc., (NASDAQ: SGEN) securities during the period between October 27, 2016, and December 23, 2016, inclusive (the "Class Period"). Seattle Genetics, a biotechnology company, develops and commercializes targeted therapies for the treatment of cancer worldwide. ...
Jan 20, 2017 08:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Seattle Genetics Inc. and Certain Officers - SGEN
NEW YORK, Jan. 20, 2017 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. ("Seattle Genetics" or the "Company") (NASDAQ:  SGEN) and certain of its officers.   The class action, filed in United States District Court, Western District of Washington, and docketed under 17-cv-00041, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Seattle Genetics securities between October 27, 2016 and December 23, 2016, both dates inclusive (the "Class Period"), seeking to recover compensable damages...
Jan 19, 2017 05:25 pm ET
SEATTLE GENETICS INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the Western District of Washington against Seattle G
NEW YORK, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP   announces that a class action lawsuit has been filed against Seattle Genetics Inc.  (“Seattle Genetics” or the “Company”) (NASDAQ:SGEN) and certain of its officers.    The class action,  filed in  United  States District  Court for the Western  District  of Washington is on behalf of a class consisting of all  persons  or  entities  who purchased  or  otherwise  acquired  Seattle Genetics securities between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”)....
Jan 11, 2017 04:22 pm ET
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Seattle Genetics, Inc. To Contact The Firm Before Lead Plaintiff Deadline
NEW YORK, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”) (NASDAQ:SGEN) of the March 13, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers....
Jan 11, 2017 02:59 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline - March 13, 2017
NEW YORK, Jan. 11, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Seattle Genetics, Inc. ("Seattle Genetics" or the "Company") (NASDAQ: SGEN) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Seattle Genetics securities between October 27, 2016 through December 23, 2016, both dates inclusive (the "Class Period"). Such investors are advised to join this case by visiting the firm's site: http://www.bgandg.com/sgen. ...
Dec 28, 2016 10:15 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Seattle Genetics, Inc. (SGEN)
NEW YORK, Dec. 28, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Seattle Genetics, Inc. ("Seattle Genetics" or the "Company") (NASDAQ: SGEN). Such investors are advised to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/sgen. ...
Dec 27, 2016 10:10 pm ET
SEATTLE GENETICS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Seattle Genetics, Inc. To Contact The Firm
NEW YORK, Dec. 27, 2016 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Seattle Genetics, Inc. ("Seattle Genetics" or the "Company") (NASDAQ: SGEN)....
Dec 27, 2016 02:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Seattle Genetics, Inc. - SGEN
NEW YORK, Dec. 27, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Seattle Genetics, Inc. ("Seattle Genetics" or the "Company") (NASDAQ: SGEN).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Jul 28, 2016 10:31 am ET
Learn how to target a 13% return on Under Armour, or get option-trade ideas on SPDR Gold Trust, Seattle Genetics, Priceline and Lockheed Martin Corporation or any stock you choose
CHICAGO, July 28, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GLD, LMT, PCLN, SGEN, and UA....
Jun 11, 2016 03:30 am ET
Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
COPENHAGEN, Denmark, June 11, 2016 /PRNewswire/ -- Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted data at the 21st Congress of the European Hematology Association (EHA) taking place in Copenhagen, Denmark, June 9-12, 2016, evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in frontline patients with acute myeloid leukemia (AML) who had declined intensive therapy. 33A is an investigational antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics' newest technology, comprising an engineered cyst...
Jun 06, 2016 09:00 am ET
Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
TOKYO and CHICAGO, June 6, 2016 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Seattle Genetics, Inc. (NASDAQ: SGEN) today presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016 in Chicago, IL. ...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.